Therapeutic Efficacy of Micrococcus Luteus Rpf Domain and its Mutants against Mycobacterium Tuberculosis in Mice

SHANG Shu-qin,ZHAO Yong,ZHAO Shan-min,ZHANG Cai-qin,SHI Chang-hong

DOI: https://doi.org/10.13241/j.cnki.pmb.2013.06.020

2013-01-01

Abstract:Objective: To investigate therapeutic efficacy of Micrococcus luteus Rpf domain and its mutants E54K(Rpfd1),E54A(Rpfd2) and E54K+D48A(Rpfd3) against Mycobacterium tuberculosis infection mice.Methods: Recombinant M.luteus Rpf domain(Rpfd) and its mutants E54K(Rpfd1),E54A(Rpfd2),E54K + D48A(Rpfd3) were expressed in E.coli BL21 and purified by GST affinity chromatography.BALB/c mice were infected with the H37Rv strain via the tail vein at a dose of 105 CFU/mouse.Four weeks after infected,the mice were randomly divided into six groups.Four groups were treated with the purfied protein Rpfd,Rpfd1,Rpfd2 and Rpfd3,respectively,three times with 2-week intervals.The drug treated group was co-administered isoniazid(INH,54.25 mg/L) with rifampicin(RFP,52.5 mg/L).The mice in the control group received only saline(negative control).At 13 weeks post-infection Determination of bacterial burden in lung and histopathology were performed.Results: The expressed proteins can specific bind with anti-Rpfd mAb,showed a 32 kDa band.At 11 weeks and 13 weeks post-infection,the bacterial burden of lungs in mice that received Rpfd,Rpfd1 and Rpfd2 is significantly lower than that in the saline treated group(P<0.05) and Rpfd3 group,but not significantly effective compared with that in the INH+RFP treated group.Conclusion: After infected by MTB,the mice were treated by Rpfd protein immune therapy.And the treatment result showed that Rpfd,mutant Rpfd1 and Rpfd2 protein can significantly reduce the lung load count,and induced lymphocyte value-added,and provides a theoretical basis and experimental basis for the preparation of MTB immune treatment vaccine by using Rpf structure domain mutant.